A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 61,300 shares of CRVS stock, worth $498,982. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,300
Previous 113,400 45.94%
Holding current value
$498,982
Previous $206,000 56.8%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.78 - $5.92 $92,738 - $308,432
-52,100 Reduced 45.94%
61,300 $323,000
Q2 2024

Aug 14, 2024

SELL
$1.36 - $2.29 $97,512 - $164,193
-71,700 Reduced 38.74%
113,400 $206,000
Q1 2024

May 15, 2024

SELL
$1.76 - $2.41 $88,880 - $121,705
-50,500 Reduced 21.43%
185,100 $329,000
Q4 2023

Feb 14, 2024

SELL
$1.08 - $1.92 $14,364 - $25,536
-13,300 Reduced 5.34%
235,600 $414,000
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.97 $98,841 - $208,197
70,100 Added 39.21%
248,900 $363,000
Q2 2023

Aug 14, 2023

SELL
$1.0 - $3.86 $8,500 - $32,810
-8,500 Reduced 4.54%
178,800 $409,000
Q1 2023

May 15, 2023

SELL
$0.65 - $0.92 $47,450 - $67,160
-73,000 Reduced 28.04%
187,300 $170,000
Q4 2022

Feb 14, 2023

SELL
$0.74 - $1.04 $162,652 - $228,592
-219,800 Reduced 45.78%
260,300 $221,000
Q3 2022

Nov 14, 2022

BUY
$0.71 - $1.17 $75,757 - $124,838
106,700 Added 28.58%
480,100 $393,000
Q2 2022

Aug 15, 2022

SELL
$0.87 - $2.03 $38,106 - $88,913
-43,800 Reduced 10.5%
373,400 $370,000
Q1 2022

May 16, 2022

SELL
$1.46 - $2.48 $505,452 - $858,576
-346,200 Reduced 45.35%
417,200 $684,000
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $1.79 Million - $4.05 Million
763,400 New
763,400 $1.84 Million
Q3 2021

Nov 15, 2021

SELL
$1.89 - $8.53 $544,887 - $2.46 Million
-288,300 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$2.46 - $3.14 $9,102 - $11,618
-3,700 Reduced 1.27%
288,300 $770,000
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $835,120 - $1.39 Million
292,000 New
292,000 $899,000
Q3 2020

Nov 16, 2020

SELL
$2.6 - $5.37 $95,888 - $198,045
-36,880 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$2.01 - $4.05 $16,079 - $32,400
8,000 Added 27.7%
36,880 $100,000
Q1 2020

May 15, 2020

BUY
$1.74 - $5.98 $21,402 - $73,554
12,300 Added 74.19%
28,880 $61,000
Q4 2019

Feb 14, 2020

BUY
$2.56 - $5.44 $42,444 - $90,195
16,580 New
16,580 $90,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $379M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.